H. pylori
Nov 20, 2023
Phathom Secures Dual FDA Approvals for Voquezna Following Impurity Setback
Within a three-day period, Phathom Pharmaceuticals achieves dual FDA approvals for Voquezna, its groundbreaking heartburn medication. The first approval on 30 October involves the reformulation of Voquezna to address Helicobacter pylori infection, followed by a second approval on 01 November for treating gastroesop...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
